Title:New Antimycobacterial Leads from Multicomponent Hydrazino-Ugi Reaction
VOLUME: 12 ISSUE: 2
Author(s):Ekaterina Lakontseva, Ruben Karapetian and Mikhail Krasavin
Affiliation:Institutes of Chemistry (IC) and Translational Biomedicine (ITBM), Saint Petersburg State University, 7/9 University Embankment, St. Petersburg 199034, Russian Federation.
Keywords:Isoniazid, pyrazinamide, hydrazino-Ugi reaction, isocyanide-based multicomponent reactions, antitubercular
chemotherapy, therapeutic window.
Abstract:Background: Previously, modification of isoniazide- and pyrazinamide-derived pharmacophores
via the Ugi multicomponent reaction proved to be an effective strategy to obtain efficacious
and non-cytotoxic antimycobacterial leads.
Objective: To apply the hydrazino-Ugi reaction developed in our group toward modifying these
pharmacophores with similar appendages as reported previously; to create hydrolytically more stable
compounds which are based on acyl hydrazine, rather than diamide backbone.
Method: Six hydrazino-Ugi products were synthesized and modified at the reactive nitrogen atom via reductive alkylation.
Additionally, by conducting the hydrazino-Ugi reaction in methanol, three methyl ester by-products were obtained
and tested alongside the main library. Compounds were screened against M. tuberculosis H37Rv strain and checked for
cytotoxicity vs. HEK293 cells. Hydrolytic stability of a model Ugi and one of the newly synthesized hydrazino-Ugi products
was compared in rat plasma stability experiments.
Results: 6 out of 20 compounds prepared and tested, displayed potent inhibition of M. tuberculosis growth and virtually
no cytotoxicity in the testing concentration range. The stability of a sample hydrazino-Ugi product in rat plasma was over
3 times higher compared to that of one of the Ugi products reported earlier.
Conclusion: Hydrazino-Ugi reaction represents an effective way to modify classical antitubercular chemotypes and generate
compounds endowed with specific antimycobacterial activity. These are new, hydrolytically stable leads for the future
antitubercular therapy development.
